CROX Crocs, Inc. Insider Trading

CEO Andrew Rees sells 32,688 shares across 3 transactions for $3,860,284.00 at Crocs; prior similar-ticker sales preceded 90d declines.

Andrew Rees, CEO of Crocs, executed 3 separate sales totaling 32,688 shares (32.7K shares) for $3,860,284.00 on 2026-06-05 at a blended average price of $118.09, reducing his holdings from 775,981 to 743,293 shares (a -4.2% reduction). This sale is noteworthy because his prior open-market sale at Crocs on 2024-06-17 was followed by a 90-day decline (-19.6%), and his cross-ticker track record shows 100% of prior sells were well-timed at the 90-day mark (avg 90d return -19.6%). The current price of $127.77 stands above the transaction price ($118.09), but the stock's rapid near-term momentum (+23.3% over 30 days, +58.9% over 90 days) follows the timing pattern observed in the CEO's prior exit. Investors should note that Crocs reported negative full-year net income in its most recent fiscal year despite current profitability in the latest quarter ($137.6M net income), providing a mixed fundamental backdrop against which to interpret the CEO's execution.

EVP Anne Mehlman sold 12,145 CROX shares at $100.06 on 2026-02-20; prior 5 same-ticker sales were 100% well-timed (90d declines).

Anne Mehlman, EVP & Crocs Brand President, sold 12,145 shares at $100.06 on 2026-02-20, reducing holdings by 8.5% to 131,112 shares. Her timing pattern at CROX is notable: all 5 prior sales at this ticker (each on 2024-06-17) posted negative 90-day returns ranging from -17.7% to -19.9%, yielding a 100.00% well-timed rate at the same-ticker level. The current stock price of $96.69 sits 19.6% below the 52-week high of $120.26, consistent with the historical pattern of her prior sales preceding declines. Notably, the company reported an annual net loss in its most recent full fiscal year despite current-quarter profitability ($145.8M net income on $996.3M revenue), and annual revenue contracted 1.5% year-over-year, creating a backdrop of mixed financial signals.

Director John B Replogle bought 3,000 shares of CROX at $74.50 on 2025-11-11 for $223,500; stock down 38.1% from 52-week high.

John B Replogle, a Director, purchased 3,000 shares of Crocs at $74.50, bringing his total holdings to 18,417 shares—a 19.5% increase in position size. The purchase occurred as CROX trades 38.1% below its 52-week high of $120.26 and has declined 8.6% over the past 30 days. Replogle's prior trades at CROX show mixed timing: 3 of 5 prior buys were well-timed at the 90-day mark, with results ranging from +24.2% to -13.0%. His cross-ticker track record shows an average 90-day return of +3.8% with a 55.56% win rate. The company's fundamentals show revenue of $996.3M and net income of $145.8M in the latest quarter, with annual growth of 3.5% and a P/E of 21.15. The current market conditions present a meaningful valuation shift from the 52-week peak, though near-term momentum remains negative.

CFO Susan L. Healy bought 2,000 CROX shares at $76.56 on 2025-08-12; stock now -43.0% from 52-week high, down -15.7% in 30 days.

Susan L. Healy, EVP and Chief Financial Officer, purchased 2,000 shares worth $153,120.00 at $76.56, expanding her CROX holdings to 50,078 shares. The timing context is notably unfavorable: CROX has declined -43.0% from its 52-week high and -15.7% in the past 30 days, placing the transaction near a depressed price point. However, Healy's trading history at this ticker shows limited predictive power—her one prior CROX purchase in November 2024 yielded -10.8% over 90 days, and across all her open-market transactions, she has achieved a 0% win rate at the 90-day horizon. The company faces structural headwinds: net income stands at $-492.3M against revenue of $1.1B, despite annual revenue growth of +3.5%. This buy occurs in a company under financial stress with an insider whose timing pattern has not demonstrated accuracy in either direction.

Director Replogle purchases 3,261 CROX shares in 2 transactions for $250,084.42 ($76.69 avg) as stock down -28.9% in 90 days

JOHN B REPLOGLE, Director at Crocs, made 2 separate open-market purchases totaling 3,261 shares at a blended average price of $76.69, increasing his holdings by 26.8% to 15,417 shares post-transaction. The purchases occurred as CROX trades at $83.40 (current), down -28.9% over 90 days and -43.4% from its 52-week high of $147.40, creating a substantially cheaper entry point than recent historical levels. However, Replogle's prior buy history at this ticker shows mixed near-term outcomes: his 3 previous CROX purchases had 30-day returns of -6.2%, +17.9%, and -1.0%, with only 1 of 3 achieving positive 90-day returns, suggesting timing precision at this equity has been inconsistent despite the current valuation discount.

Director Thomas J Smach sells 9,139 CROX shares at $109.47; holds 109,458 post-sale amid stock +29.9% in 30 days

Director Thomas J Smach sold 9,139 shares (9.1K shares) of Crox at $109.47 on 2025-05-09, reducing holdings by 7.7% to 109,458 shares. The sale occurred as CROX posted a 30-day return of +29.9% and 90-day return of +35.4%, with the stock currently trading at $120.26, approximately 10% above the sale price. Smach's cross-ticker track record shows a single prior open-market sell that achieved a 90-day well-timed rate of 100.00%, though his prior CROX transactions display a consistent pattern of poor timing: one prior CROX sell (May 2024) was well-timed, but four prior buys at this ticker in July–August 2023 all showed negative 90-day returns ranging from -6.1% to -18.7%. The current sale occurs against a backdrop of strong recent price momentum and a relatively modest valuation (P/E of 7.04), leaving the directional signal from this trade ambiguous.

EVP Shannon Sisler sold 4,659 shares of CROX at $109.75 on 2025-02-21; stock down 32.6% from 52-week high.

Shannon Sisler, Chief People Officer, sold 4,659 shares at $109.75, reducing her holdings by 13.7% to 29,299 shares. The sale occurred when CROX traded $109.75, while the stock currently sits at $107.60, down 32.6% from the 52-week high of $159.68. Despite recent strength with a 4.8% gain over 30 days and 1.4% over 90 days, the stock remains in significant drawdown from peak levels. With a low P/E of 6.08 and strong fundamentals (net income of $199,801,000.00 on revenue of $1,062,200,000.00 with 3.5% annual growth), the sale appears to reflect individual portfolio adjustment rather than a broad fundamental deterioration signal. The transaction size and remaining substantial holdings provide limited directional insight for investors.

CROX CDO Adam Michaels sells 15,000 shares (14.4% of holdings) for $1,600,324.50 on 2025-02-18

Adam Michaels, EVP and Chief Digital Officer, executed 2 separate sales totaling 15,000 shares for $1,600,324.50 at blended average price $106.69, reducing his holdings from 104,323 shares to 89,323 shares. The sales occurred at prices near the bottom of the recent run-up: the stock has gained 11.0% in the last 30 days and currently trades at $110.95, 30.5% below its 52-week high of $159.68. Michaels retains 89,323 shares post-transaction, representing a modest 14.4% reduction rather than a complete exit. The company's fundamentals remain solid with a P/E of 6.27 and net income of $199,801,000.00 on revenue of $1,062,200,000.00.

CFO Healy buys 1,000 shares of CROX at $99.70; stock down 28.9% in 30 days, near 52-week low

CFO Susan L. Healy purchased 1,000 shares at $99.70 while Crocs stock has declined 28.9% over the prior 30 days and trades $99.86 versus a 52-week high of $159.68. Her post-transaction holdings total 22,652 shares, representing a 4.6% increase from prior holdings. Despite this acquisition, the stock's recent steep drawdown and current valuation position at 37.5% below its annual peak present a mixed signal: the buy occurs amid significant recent weakness rather than at elevated prices. The company's fundamentals remain solid with annual revenue growth of 11.5% and a P/E of 6.97, but near-term price momentum is notably negative.

Director Replogle buys 2,240 CROX shares at $112.60, raising stake 31.7% to 9,304 shares

Director John B Replogle purchased 2,240 shares of Crocs at $112.60 on 2024-10-30, expanding his holdings by 31.7% from 7,064 to 9,304 shares. The purchase occurs as the stock trades at $109.00, down 24.7% over the prior 30 days and 31.7% below the 52-week high of $159.68, yet the company maintains a low P/E of 7.61 with strong fundamentals: $1.1B quarterly revenue, $199.8M net income, and 11.5% annual revenue growth. His prior open-market buy at this ticker on 2024-08-02 returned +17.9% within 30 days, and his buy on 2024-03-14 returned +24.2% over 90 days, establishing a track record of well-timed entry points at CROX; however, his cross-ticker average 90-day return of +6.8% (50% win rate across 5 prior buys) is modest, and this current purchase follows a sharp 30-day drawdown that warrants scrutiny as to whether the timing reflects genuine conviction or opportunistic accumulation into weakness.